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Abstract
Background: IgAN is the most common type of glomerulonephritis in the world. Between 15 and
40 percent of adults and children diagnosed with IgAN eventually progress to ESRD. Despite the
need for effective treatment strategies, very few RCTs for IgAN have been performed. The most
effective therapies for IgAN appear to be corticosteroids, ACEi, and FOS that contain a high
concentration of omega 3 fatty acids. While ACEi and FOS are generally well tolerated with
minimal side effects, the use of high dose steroids over a long course of therapy is often associated
with significant morbidity.
Objective of the study: The objective of the study is to test the hypothesis that treatment with
the immunosuppressive agent, MMF, will lead to significant and sustained improvement in urinary
protein excretion in patients with IgAN who have been pre-treated (and continue to be treated)
with ACEi and FOS compared to a placebo control group of patients receiving comparable doses
of ACEi and FOS without MMF.
Design: After a three month treatment period with the ACEi, lisinopril and the FOS, Omacor®,
100 (2 × 50) patients with IgAN and a urinary P/C ratio ≥ 0.6 (males) and ≥ 0.8 (females) and an
estGFR ≥ 40 ml/min/1.73 m2 will be randomized to treatment with either MMF or placebo for one
year. All patients will be followed off study drug for a second year, but will continue treatment with
lisinopril and Omacor® for the two year duration of the study. The primary outcome measure of
change in urine P/C ratio will be assessed at the end of years one and two.
Background
IgAN is the most common type of glomerulonephritis in
the world [1,2]. Between 15 and 40 percent of adults and
children diagnosed with IgAN will eventually progress to
end stage renal disease (ESRD) [3-6]. Effective treatment
strategies are needed to prevent ESRD in patients with this
condition. To date, the following RCTs for treatment of
IgAN have been completed: FOS vs. placebo with the pri-
mary endpoint of decline in kidney function [7], intrave-
nous and oral corticosteroids with the primary endpoint
of decline in kidney function [8], oral corticosteroids and
azathioprine vs. supportive care with the primary
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endpoint of reduction in urinary protein excretion [9],
"low-dose" oral corticosteroids with the primary endpoint
of reduction in urinary protein excretion [10], ACEi vs.
placebo with the primary endpoint of reduction of pro-
teinuria [11], MMF vs. prednisone with the primary end-
point of reduction of proteinuria [12], MMF vs. placebo
with the primary endpoint of reduction of proteinuria
[13-15].
The results of this study group's first trial of FOS vs. alter-
nate day prednisone vs. placebo with the primary end-
point of decline in kidney function [16] have recently
been published in abstract form [17]. We found no signif-
icant difference with respect to decline in renal function
among the alternate-day prednisone, FOS and placebo
groups. We did find a significant decline in proteinuria
after two years of treatment for both the prednisone and
FOS groups as compared to the placebo group.
Ongoing RCTs using decline in GFR as the primary out-
come measure include a European pediatric study and
comparing ACEi vs. placebo [18], an Italian study com-
paring ACEi and prednisone to ACEi alone [19], and
another Italian study examining intravenous and oral cor-
ticosteroids with and without azathioprine [20].
The most effective therapies for IgAN appear to be FOS
that contain a high concentration of omega 3 fatty acids
[7], corticosteroids [8-10], and ACEi [11]. However, the
use of moderate to high dose steroids over a long course
of therapy is may be associated with significant morbidity
and the most recent results of the effect of FOS suggest
that such therapy may only be successful in delaying pro-
gression for a few years rather than permanently prevent-
ing progressive disease [21]. FOS and ACEi inhibitors are
widely used for the treatment of IgAN and are usually well
tolerated. Hence we believe that giving both FOS and
ACEi to all patients in the proposed study is warranted
and will greatly enhance patient recruitment by providing
some form of treatment for all subjects in the trial.
MMF is an immunosuppressive agent that acts to suppress
antibody formation by B-cells through impairment of de-
novo purine synthesis [22]. Case series suggest that MMF
may be effective in reducing proteinuria in a variety of
glomerular diseases including IgAN [23-25], and two
recent Chinese RCTs found MMF to be significantly better
than prednisone for reduction of proteinuria in patients
with IgAN [12,13]. However, two other recent RCTs
showed no benefit for MMF in reduction in proteinuria in
patients with IgAN [14,15].
Methods/design
Objective of the study
To undertake a multicenter, RCT designed to test the
hypothesis that treatment with MMF will lead to signifi-
cant and sustained improvement in proteinuria in
patients with IgAN who have been pre-treated (and con-
tinue to be treated) with ACEi and FOS compared to a pla-
cebo control group of patients receiving comparable doses
of ACEi and FOS without MMF.
Rationale for using change in proteinuria as a primary 
endpoint
The most obvious endpoint for treatment failure in
patients with IgAN is progression to ESRD. However,
since the period from diagnosis to ESRD in patients with
normal renal function at onset may be over 10 years, most
studies of therapy for IgAN have used surrogate end-
points, such as improvement or stability of serum creati-
nine, or decline in amount of proteinuria. Deterioration
in renal function, (e.g., 50% loss of function), has been
the surrogate endpoint that most closely associates with
the primary endpoint of progression to ESRD.
Considerable data from clinical trials suggest that renal
function will be protected and proteinuria reduced in
patients with non-diabetic glomerular disease treated
with ACEi [26-28]. An unproved assumption is that signif-
icant lowering of urinary protein excretion will result in
preservation of renal function. If this assumption is in fact
true, then reduction in protein excretion in a short term
study of two years may be associated with preservation of
renal function for a much longer (5 to 20 years) or even
indefinite period of time. This is the basis for our decision
to use reduction in proteinuria as the primary outcome
measure in this study.
Study design
This is a multicenter, double-blind placebo-controlled,
RCT designed to test the efficacy of MMF in patients with
IgAN who are at risk for development of progressive dis-
ease. All subjects will receive treatment with Omacor®and
lisinopril during a 3-month lead in period and for the sub-
sequent 2-year period of study. Adult subjects who are
unable to tolerate lisinopril may exit the study or may be
converted to losartan and continue in the study. Each sub-
ject will receive a year of treatment with the study drug
(MMF) or placebo followed by a year of follow-up off
study drug. This multicenter clinical trial will be con-
ducted in up to 50 clinical centers where patients will be
recruited and studied. The study will be coordinated by
the ACC at Medical City Dallas Hospital, Dallas, TX.
Primary outcome measure
The primary outcome measure will be change from entry
level in urine P/C ratio. Data for this outcome will beBMC Nephrology 2004, 5 http://www.biomedcentral.com/1471-2369/5/3
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examined every 6 months until the end of the study two
years after randomization.
Secondary outcome measure
The secondary outcome measure will be change in estGFR
[29]. We realize that the likelihood of detecting significant
changes in GFR in this short-term study is remote.
Summary of study phases
There are four phases of study for each subject. Phase 1 or
the screening phase will be from one to four week dura-
tion. During this phase each potential subject will be eval-
uated to determine if he/she is eligible for the study. The
renal biopsy report will be examined to confirm the diag-
nosis of IgAN and to determine the severity of renal injury
at the time of biopsy. Subjects are eligible for entry if pro-
teinuria determined in the central laboratory is over 1 gm
per day on a 24-hour collection or the UPr/Cr ratio on an
aliquot from that collection is ≥0.6 in a male taking an
ACEi or >0.8 female in a taking an ACEi. The minimum
acceptable estGFR at entry is ≥50 ml/min/1.73 m2 for
subjects who are not taking an ACEi and ≥40 ml/min/1.73
m2 for subjects who are taking an ACEi.
Phase 2 or the lisinopril/Omacor® lead-in phase will last
for three months. During this phase each subject will be
established on a stable dose of both lisinopril (or losartan
if necessary) and Omacor®. At the end of this phase male
subjects with a UPr/Cr ratio ≥ 0.6 and female subjects with
a UPr/C ratio ≥ 0.8 will be eligible for randomization. The
estGFR must be ≥40 ml/min/1.73 m2  prior to
randomization.
Phase 3 is the study drug treatment phase and will last for
12 months. Due to the large number of centers required
to recruit sufficient subjects, stratification by center is
impractical. Block randomization will be performed in
equal blocks of 4 for each of the two strata. After the ACC
has determined that the patient is eligible for the study,
the biostatistician, based upon the randomization scheme
constructed using a computer-based pseudo-random
number generator, will determine the treatment group
assignment. The biostatistician will notify the study phar-
macist of the assignment and he/she will arrange for deliv-
ery of the appropriate study medication (MMF or matched
placebo) the center investigator responsible for manage-
ment of the patient. Subjects will receive MMF or placebo
at a dose that is based on body size.
During phase 4, the post-treatment Phase subjects will be
monitored carefully to determine if they show changes in
urine Pr/Cr ratio or estGFR after MMF/placebo has been
discontinued. (They will still receive Omacor® and lisino-
pril (or losartan if necessary).
Inclusion criteria
Criteria for inclusion in the study are: 1) patient age above
7 and less than 70 years, 2) renal biopsy diagnostic for
IgAN based on immunohistologic staining for IgA that is
greater than or equal to staining for IgG and IgM after the
biopsy report has be evaluated by one of the study pathol-
ogists (entry into the study does not depend upon any
specific time interval between the time of the renal biopsy
and the time of entry), 3) ability to swallow the oral med-
ications used in the study, 4) signed informed consent by
subjects ≥ 18 years of age, and parent/guardian of any sub-
ject < 18 years of age with a subject aged ≥ 7 years to <18
years of age also signing an age-appropriate assent form,
5) urine Pr/Cr ratio ≥ 0.6 for males and ≥ 0.8 for females
prior to randomization, 6) for female subjects of child-
bearing potential a negative pregnancy test one week prior
to starting lisinopril, and again less than one week before
starting MMF or placebo.
Exclusion criteria
Criteria for exclusion from the study are: 1) clinical and
histologic evidence of systemic lupus erythematosus, 2)
well-documented history of Henoch-Schönlein purpura
(previous non-specific abdominal pain or rash does not
exclude a subject), 3) cirrhosis, chronic active liver dis-
ease, hepatitis B, hepatitis C, 4) history of significant gas-
trointestinal disorder (e.g.: severe chronic diarrhea or
active peptic ulcer disease, 5) HIV, 6) any systemic infec-
tion or history of serious infection within one month of
entry 6) ANC < 2000/mm3, 7) HCT < 28% (anemic sub-
jects may be reevaluated after the anemia has been
treated), 8) estGFR < 40 ml/min/1.73 m2 at time of ran-
domisation (it is acceptable for the estGFR to fall to less
than 40/ml/min1.73 m2 during treatment with MMF or
placebo provided the level prior to randomization is still
≥60% of the pre-entry value), 9) known contraindication
to the administration of MMF, OMACOR® or lisinopril (or
losartan if used instead of lisinopril), 10) other major
organ system disease or malignancy except skin cancer
fully excised more than 5 years prior to entry, 11) current
or prior treatment with MMF or azathioprine, 12) preg-
nancy or breast feeding at time of entry or unwillingness
to comply with measures for contraception, 13) current or
recent (within 30 days) exposure to any investigational
drug.
Exit criteria (reasons for permanently discontinuing study 
medication)
Reasons for permanently discontinuing study medication
are: 1) ingestion of prohibited medication (MMF, azathi-
oprine, cyclophosphamide, cholestyramine; NSAIDs, Cox
2 inhibitors, cimetidine, vitamin E in doses greater than
those provided in a daily multivitamin tablet, 2) a lipid
lowering medication other than cholestyramine (e.g. a
statin) begun after study entry (such medication may beBMC Nephrology 2004, 5 http://www.biomedcentral.com/1471-2369/5/3
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continued if the subject was receiving it at the time of
entry, 3) corticosteroid therapy to treat the IgAN, (a short
course (<7 days) may be given for an acute non-renal con-
dition e.g., an acute asthma episode), 4) a major adverse
event (e.g., life-threatening infection, allergic reaction to
MMF, severe gastrointestinal disorder, or development of
any malignancy, 5) persistent gastrointestinal disorder of
moderate severity after MMF dose Step 2 reduction for 2
weeks, 6) HCT persistently lower than 25% after MMF
dose Step 2 reduction for 2 weeks, 7) ANC persistently
lower than 1500/mm3 after MMF Step 2 reduction for 2
weeks, 8) ANC lower than 1000/mm3 at any time (see
page 6 for MMF step reductions in dosage), 9) administra-
tion of a live viral vaccine, 10) patient/parent withdrawal
of consent to participate, 11) patient moving out of the
area to a location with participating center within a rea-
sonable distance, 11) pregnancy, 12) sexually active
female not using two forms of birth control, 13) interrup-
tions of MMF treatment for 28 days or more cumulatively,
or any single interruption of more than 21 consecutive
days, 14) inability to tolerate lisinopril (or losartan in
adult patients), 15) estGFR less than 60% of level reported
at pre-entry visit at any time during the study confirmed
on a repeat specimen one month later.
Study medications
The dose of MMF to be given during most of the study will
be between 25 mg/kg/day and 36 mg/kg/day with a max-
imum dose 1 gm BID. The initial dose to be used (in the
first 2 weeks of therapy) will be approximately 1/2–2/3 of
the full dose (as shown in the Table below). Roche Labo-
ratories will provide MMF capsules and matching placebo
capsules. Capsules are produced in strength of 250 mg
and the dose used will be based upon the weight of the
subject (Table 1).
If a subject develops gastrointestinal toxicity from MMF or
HCT is <25% or ANC is 1000–1500, the dose will be
reduced in accordance with Step 1 of a specific protocol
(Table 2). If after 2 weeks, any of these abnormalities per-
sist, the dose of MMF will be reduced again in accordance
with Step 2 of the protocol (Table 2). If any of the prob-
lems persist 2 weeks after the Step 2 reduction, MMF will
be discontinued.
In a case of severe signs of MMF toxicity, more rapid
reduction of MMF is allowed. If ANC is <1000, MMF must
be stopped immediately. After a dose reduction or inter-
ruption, unless medically contra-indicated, MMF will be
reinstituted within 14 to 21 days in increments until the
protocol recommended MMF dose is achieved. The dose
will be increased in reverse order to that given in the above
table until the optimal tolerable dose is found. A
maximum stepwise increments of 500 mg is used for sub-
jects ≥ 55 kg and 250 mg for subjects < 55 kg.
Occurrence of gastrointestinal toxicity requires a decision
as to whether or not to alter MMF dosing. This decision is
Table 1: Weight-based schedule for MMF dosing
Patient weight (Kg) Initial dose (mg) AM PM Full dose (mg) AM PM Full dose in mg/Kg/day
25 – 30 250, 250 500, 250 25 – 30
30 – 40 250, 250 500, 500 25 – 33
40 – 45 500, 250 750, 500 28 – 31
45 – 50 500, 500 750, 750 30 – 33
50 – 55 500, 500 1000, 750 32 – 35
≥55 500, 500 1000, 1000 ≤36
Table 2: Protocol for daily dose reduction for MMF/Placebo
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based on several factors. Diarrhea will be treated as fol-
lows: infectious causes (e.g., C. difficile and enteropatho-
gens) should be ruled out and treated if necessary. Once
these infectious causes have been excluded, agents such as
Lomotil or tincture of opium may be used to decrease
diarrhea so that MMF dosing can be maintained. Finally,
if diarrhea persists, the MMF dose will be reduced as per
the above protocol.
Omacor® (omega-3 fatty acids) is provided by the study
and dispensed at a dose of 4 grams per day for all patients
with body surface area ≥1 m2. The dose will be adjusted to
the nearest number of capsules corresponding to the body
surface area in patients less than 1 m2. The active ingredi-
ent in Omacor® capsules is an oil which consists of ethyl
esters, mainly EPA and (DHA). The concentration of EPA
ethyl ester is approximately 47% and DHA ethyl ester
approximately 37%. In addition the concentrate contains
ethyl esters of other omega-3 fatty acids, and also ethyl
esters of other fatty acids. Four mg of α-tocopherol is
added as an antioxidant.
Lisinopril will be dispensed at an initial dose of 5–20 mg
per day depending on the size of the subject (Table 3). If
this is well tolerated the dose will be doubled after 1
month of therapy to 10–40 mg per day. For subjects that
are hypertensive after the "higher dose" of lisinopril has
been given for one month, the dose may be further
increased to twice the "higher dose" (maximum 20 – 80
mg/day depending on size of subject).
Treatment of hypertension
Hypertension will initially be treated with lisinopril, using
the doses listed above. If a patient is on an anti-hyperten-
sive medication other than lisinopril at the time of entry,
that medication will be stopped and, if possible, control
of the patient's hypertension will be obtained using lisi-
nopril. Persistent hypertension will be defined by a systo-
lic BP > 135 mm/Hg, a diastolic BP > 85 mm/Hg, or either
level at > 95th percentile for age on two consecutive visits.
For subjects who have persistent hypertension despite
receiving the higher dose of lisinopril, additional BP med-
ication will be used with the selection of medication
based upon the local physician's preference. However, the
use of lisinopril doses greater than 20–80 mg/day, and/or
angiotensin receptor blockers (other than losartan substi-
tution for lisinopril) is prohibited by the study.
This strategy of treatment for hypertension in patients
entered into this study with a non-ACEi medication is
both ethical and will reduce the chance of the treatment
given for hypertension becoming a confounding variable
for the trial.
Clinical safety monitoring
Participating investigators will report within 72 hours all
serious adverse events that occur after study medication
starts. Members of the SMC evaluate this information.
They will disseminate reports of serious adverse drug
reactions to all participating centers for submission to
their respective IRBs. This centralized function permits
ongoing evaluation of risks associated for patients with
IgAN taking MMF and will enhance prompt dissemina-
tion of information as appropriate. Uniform reporting of
all serious adverse events to the ACC in this study will
make possible a much more accurate determination of the
degree to which any SAE that may be encountered is, in
fact, drug related.
The investigator is required to report all treatment-emer-
gent adverse events that are observed or reported during
study phase 2 (i.e., treatment phase). This applies regard-
less of a) the clinical significance or b) the assessment of
study drug causality. All such events must be recorded on
the AEF.
An adverse event is defined as any untoward medical
occurrence in a patient who takes the study medication. It
does not necessarily have to have a causal relationship
with this treatment. This may be any unfavorable and
unintended sign (e.g., abnormal laboratory finding),
symptom or disease, which is observed after exposure to
the study medication, whether or not considered, related
to the treatment.
Table 3: Weight-based dosing schedule for lisinopril
Patient weight (kg) Initial daily dose (mg) Higher daily dose (mg) Initial/Higher dose in mg/kg/day
<25 5.0 10 ≥0.20/0.40
25 – 35 7.5 15 0.21 – 0.3/0.42 – 0.60
35 – 45 10 20 0.22 – 0.28/0.44 – 0.56
45 – 55 12.5 25 0.23 – 0.28/0.46 – 0.56
55 – 65 15 30 0.23 – 0.27/0.46 – 0.54
65 – 75 17.5 35 0.23 – 0.27/0.46 – 0.54
>75 20 40 ≤0.27 / ≤0.54BMC Nephrology 2004, 5 http://www.biomedcentral.com/1471-2369/5/3
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An adverse drug reaction is defined as a noxious and unin-
tended response to a study medication, at any dose. A
causal relationship between the study medication and the
adverse event must be at least a reasonable possibility, i.e.,
the relationship cannot be ruled out.
A SAE or reaction is any untoward medical occurrence (at
any dose) that: a) results in death, b) is life-threatening, c)
requires inpatient hospitalization or prolongs an existing
hospitalization, d) results in persistent or significant disa-
bility/incapacity or, is a congenital anomaly or birth
defect in an infant exposed prenatally. Other events that
places the subject in jeopardy or that require intervention
to prevent one of the above outcomes (e.g., pregnancy)
should also be considered serious. All SAE are reported to
the ACC within 72 hours.
A treatment-emergent event is any sign, symptom or dis-
ease that either a) is not present prior to exposure to study
medication, or b) if already present, worsens in either
intensity or frequency following exposure to study
medication.
The initial report of the SAE may be communicated by
phone, but is followed up as soon as possible by sending
an "initial" report on the SAE Form to the ACC. The nature
and severity of each event is compared with known
adverse reactions already published in the current product
information pages supplied by Roche. If it is determined
that an unexpected, serious adverse event has occurred, a
report is provided to investigators at all study sites. Each
investigator should forward the information to the local
IRB.
Situations requiring the use of excluded medications
If it is medically necessary to treat a patient with an
excluded medication that is known to interact with MMF
or affects the action of MMF, the study drug may be inter-
rupted or the dose decreased as deemed necessary by the
investigator.
If it is medically necessary to treat the patient with an
excluded medication that affects the primary outcome
measure, the investigator should again proceed in accord-
ance with the medical needs of the patient. An interrup-
tion of study medication of no more than 14 consecutive
days is permissible. If the interruption is longer, the
patient should not resume taking MMF, and should be
seen in the clinic as soon as possible. Then resume regular
scheduled visits.
Data management
Data arrives at the ACC in two forms – CRFs and LabCorp
generated reports. The CRFs are used to record the follow-
ing: 1) demographic history, 2) physical examination var-
iables, 3) study and concurrent medications, 4) adverse
events
LabCorp will report all laboratory data on standardized
report forms. LabCorp will send reports of laboratory val-
ues directly to the ACC. The Data Manager and a clinical
coordinator at the ACC will double enter data into the
database. Irrecoverable missing values will be docu-
mented with appropriate codes in the database. Periodic
computerized audit reports will be run to monitor quality
and completeness. The database is stored on a network
drive that is backed up to tape daily by the Information
Systems Department at Medical City Dallas Hospital.
In order to insure confidentiality, data from each patient
will be recorded in the computer database with a unique
contributing center code, study code, sequence number
and patient initials. Patient names are never given to Lab-
Corp or the ACC. Each study center is assigned a code
number. The ACC assigns a unique patient identification
code when the screening evaluation checklist is received.
Sample size calculation
The primary study outcome is the change in urinary pro-
tein excretion (urine Pr/Cr ratio) at the conclusion of the
three-month "lead-in" period and the level obtained at
each year of the study. A current examination of data from
patients with IgAN entered in our previous study indicates
mean baseline urine P/C ratio of 1.90 (SD = 1.80; External
Advisory Committee Report, 2001). Although a urine P/C
ratio of 1.90 reflects a reasonable baseline measure, we
expect that urine P/C ratios will fall during the three-
month "lead-in" period in response to lisinopril and to a
lesser extent, Omacor®. Previous research indicates that
more than half of patients who received ACEi for a period
of twelve months displayed a twenty-five percent reduc-
tion in their urinary protein excretion ratios [30]. In addi-
tion, at least one study indicates that a further reduction
of UPr/Cr ratios can be expected in response to FOS [31].
Based on this previous research, we expect that patients
receiving ACEi and the FOS will display nearly a forty per-
cent reduction in urine P/C ratio upon conclusion of the
three-month "lead in" period. Based on this assumption,
we hypothesize that the mean urine P/C ratio for all
patients will be 1.20 upon conclusion of the three-month
"lead-in" period. We further hypothesize that the mean
urine P/C ratio for the ACEi/FOS plus MMF group will be
0.50 (reduction of 0.70) after one year of MMF. In con-
trast, we hypothesize that for the ACEi/FOS plus placebo
group the urine P/C ratio will remain constant at 1.20
after one year of placebo. Assuming a 15% attrition rate
and a 1.80 population standard deviation, a sample size
of 50 patients per group would be required to obtain a
0.05 significance level with a power of 0.80.BMC Nephrology 2004, 5 http://www.biomedcentral.com/1471-2369/5/3
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Although a final sample size of 50 patients per group will
be needed at the commencement of phase three, many
more patients will be initially required. We expect to
screen approximately 200 patients during the phase one
screening. Based on our experience with the previous
IgAN treatment trial, we anticipate twenty-five percent of
these 200 patients will not meet the initial inclusion crite-
ria. The exclusion of these 50 patients will leave approxi-
mately 150 for inclusion in the phase two "lead-in"
period. Upon conclusion of the three-month "lead-in"
period, we expect that a third of these patients will fail to
meet the inclusion criteria. These patients will have
already displayed clinically significant benefit (i.e., urine
P/C ratio less than 0.6 for males and 0.8 for females) from
the "lead-in" treatment regimen. In summary, we plan to
screen 200 patients, to include 150 patients in the "lead-
in" phase, and to randomize 100 patients into one of two
comparison groups.
Statistical approach
Following the conclusion of the first year of the study, a
statistical summary report will be prepared. This report
will summarize the progress of the study, study patient
characteristics, and safety issues.
Baseline comparability between the two treatment groups
will be evaluated with respect to entry criteria (e.g., demo-
graphics, laboratory results). Chi-square and t-test will be
used to assess differences between the two groups on the
baseline variables. Any variables that are found to be dis-
crepant between the two groups and that are related to the
outcome variables will be treated as covariates in later
analyses.
In order to evaluate the patients' change in urine P/C
ratios, two strategies will be employed. We hypothesize
that patients treated with ACEi, FOS, and MMF will dem-
onstrate nearly a sixty percent decrease in their UPr/Cr
ratios. In contrast, we expect those patients treated with
ACEi, FOS, and placebo to maintain relatively constant
urine P/C ratios. The Kaplan-Meier method will be used to
estimate the time in which patients are likely to display
the 60% decrease in urine P/C ratio during the two-year
study period. Secondly, rate of change (slopes) in the pri-
mary outcome measures will be estimated for each
patient. These estimates will then be compared between
groups to assess for differences in rate of change between
the two treatment groups.
Publication of study results
All publications will be authored by members of the sci-
entific advisory committee. Co-authors will have contrib-
uted to the design, analysis and actual reporting of the
study.
Study investigators
Steering committee: RJ Hogg, N Nardelli, C Adkins, L Fit-
zgibbons, D Parrott, J Miller
Scientific planning committee: RJ Hogg, WA Briggs, DC
Cattran, JC Chan, JJ Dillon, RJ Falk, L Fitzgibbons, RJ Glas-
sock, JC Jennette, BA Julian, R Sibley, RJ Wyatt
Safety monitoring committee: JC Chan, JV Donadio, RJ
Glassock, L Fitzgibbons, J Miller, D Parrott
Discussion
We report the protocol of a RCT designed to test the effi-
cacy of MMF in reducing proteinuria in patients with
IgAN. This study utilizes the novel approach of examining
the use of an immunosuppressive agent (MMF) that is not
being used in conjunction with corticosteroid therapy. In
the previous study form our group, subject recruitment
was hampered by the unwillingness of some subjects to
consider the possibility of corticosteroid treatment assign-
ment and the difficulty some patients or their parents had
in being assigned to a placebo group. We anticipate better
acceptance of this protocol since corticosteroids will not
be used and subjects in both groups will be treated with
ACEi and FOS.
The use of change in urine P/C ratio as primary outcome
measure, rather than decrease in kidney function will
allow for completion of the study and analysis of data
within in a relatively short period of 4 to 5 years as
opposed to 6 to 10 years for studies that utilize change in




IgAN – IgA nephropathy
ESRD – end stage renal disease
RCTs – Randomized controlled trials
FOS – fish oil supplements
ACEi – angiotensin converting enzyme inhibitor
MMF – mycophenolate mofetil
P/C – protein to creatinine
ACC – administrative co-ordinating center
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HIV – human immunodeficiency virus
ANC – absolute neutrophil count
HCT – hematocrit
NSAID – non-steroid anti-inflammatory drug
EPA – eicosapentaenoic acid
DHA – docosahexaenoic acid
SMC – safety monitoring committee
IRB – institutional review board
AEF – adverse event form
SAE – serious adverse event
CRF – case report form
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